Perpetual Adaptive Trial
Randomization Ratio 3:1; Shared Placebo
Open Label Extension offered

Regimen A
(n=160 for each regimen)

Regimen B

Regimen C

Regimen D

3:1 Randomization within each Regimen

Zilucoplan
Placebo

Verdiperstat
Placebo

CNM-Au8
Placebo

Pridopidine
Placebo

Shared Placebo

Screening

24 weeks on investigational product (active:placebo = 3:1)

➢ as of 3/25/21

Open Label Extension

Open Label Extension

Open Label Extension

Open Label Extension

Regimen Assignment

Screening

(n=120 for active; n=40 for placebo)
How to Find a Center Near You

48 sites are actively enrolling

Contact Info of Participating Sites by State

https://www.massgeneral.org/neurology/als/research/platform-trial-sites
List of enrolling sites as of March 25, 2021
48 sites are enrolling

- Texas Neurology
- Mass General Hospital
- UTHSCSA
- Hospital for Special Care
- Holy Cross Hospital
- Thomas Jefferson
- Houston Methodist
- Henry Ford Health System
- Barrow Neurological Institute
- Ohio State University
- Northwestern University
- University of Chicago
- Wake Forest
- University of Nebraska
- Loma Linda University
- University of Washington
- University of Iowa
- Washington University
- University of Pennsylvania
- University of Michigan
- California Pacific Medical Center
- Penn State Hershey
- UMass Worcester
- University of Miami
- University of Colorado
- Cedars-Sinai
- University of Florida
- University of South Florida
- Columbia University
- University of Virginia
- Emory University
- University of Maryland
- SUNY Upstate
- Beth Israel Deaconess
- Temple University
- Dartmouth-Hitchcock
- Medical College of Wisconsin
- Spectrum Health
- University of Missouri
- University of Minnesota
- Johns Hopkins University
- University of CA Irvine
- University of Kansas
- Vanderbilt University
- University of Kentucky
- Mayo Rochester
- Duke University
- Neurology Associates
Enrollment Updates

NEWS - MAR | 9 | 2021

Healey Center for ALS Passes 50% Participant Enrollment Milestone for First 3 Regimens in the HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial, an initiative led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and conducted at sites of the Northeast ALS (NEALS) consortium, continues to gain momentum just months after launching in 2020, passing the 50% participant enrollment milestone for the first 3 regimens.

Type
News

Centers and Departments
Enrollment Updates (as of March 25, 2021)

- 372 individuals with ALS signed informed consent
- 293 individuals were assigned to a regimen
- 262 are receiving investigational product (active or placebo)

We will continue to update the ALS community on enrollment (website, webinars)

To see whether you might qualify, view the list of eligibility criteria online: https://bit.ly/3p4PrLL
Patient Navigator

Catherine Small
Allison Bulat

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

To see whether you might qualify, view the list of eligibility criteria online:
For More Updates

- **Weekly webinars**
  
  The idea of came from our Patient Advisory Committee: we are excited to be talking with you on a weekly basis and take any questions you might have.

- **Find the schedule and registration links on our website**
  
  [https://www.massgeneral.org/neurology/als/research/platform-trial-news/](https://www.massgeneral.org/neurology/als/research/platform-trial-news/)

Previously: Drug mechanism of action and science webinars

Send us webinar ideas!

- Biomarkers
- Biostatistics / Trial Design
- Get to know our sites